How long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trial

AUTOR(ES)

Bonarjee, Vernon VS

FONTE

BioMed Central

RESUMO

Long-term treatment with angiotensin-converting enzyme inhibitors reduces post-infarction morbidity and mortality in patients with left ventricular (LV) systolic dysfunction or symptomatic heart failure. Until recently, the effect of such treatment in patients with preserved LV function has not been known. The results from the Heart Outcome Prevention Evaluation trial have indicated that long-term treatment with ramipril leads to a significant reduction in cardiovascular events in patients with atherosclerotic disease, including those with prior myocardial infarction and preserved LV function. These results suggest that long-term angiotensin-converting enzyme inhibition should also be considered in post-infarction patients with normal cardiac function.

Documentos Relacionados

• Phosphorus-containing inhibitors of angiotensin-converting enzyme.
• Exercise testing in hypertensive patients taking different angiotensin-converting enzyme inhibitors
• Angiotensin‐converting enzyme inhibitor fetopathy: long‐term outcome
• Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme.
• Angiotensin-converting enzyme and male fertility